+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification



Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification



Acs Chemical Biology 7(5): 805-810



In an effort to develop improved binding antagonists of the polo-like kinase 1 (Plk1) polo-box domain (PBD), we optimized interactions of the known high affinity 5-mer peptide PLHSpT using oxime-based post solid-phase peptide diversification of the N-terminal Pro residue. This allowed us to achieve up to two orders of magnitude potency enhancement. An X-ray crystal structure of the highest affinity analogue in complex with Plk1 PBD revealed new binding interactions in a hydrophobic channel that had been occluded in X-ray structures of the unliganded protein. This study represents an important example where amino acid modification by post solid-phase oxime ligation can facilitate the development of protein-protein interaction inhibitors by identifying new binding pockets that would not otherwise be accessible to coded amino acid residues.

(PDF emailed within 0-6 h: $19.90)

Accession: 053666433

Download citation: RISBibTeXText

PMID: 22292814

DOI: 10.1021/cb200469a


Related references

Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). Bioorganic and Medicinal Chemistry Letters 22(24): 7306-7308, 2013

Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. Bioorganic and Medicinal Chemistry Letters 26(20): 5009-5012, 2016

Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 25(24): 6581-6588, 2017

Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. Bioorganic and Medicinal Chemistry 25(19): 5041-5049, 2017

Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. Bioorganic and Medicinal Chemistry 21(14): 3996-4003, 2014

A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD). Current Topics in Medicinal Chemistry 9(13): 1194-1205, 2010

A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Analytical Biochemistry 383(2): 205-209, 2008

Screening and Identification of PLK1-Polo Box binding peptides by high-throughput sequencing of phage-selected libraries. Protein and Peptide Letters 2019, 2019

Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer. Biological and Pharmaceutical Bulletin 40(9): 1454-1462, 2018

Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Chemmedchem 10(1): 158-163, 2015

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget 8(1): 1234-1246, 2016

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic Chemistry 81: 278-288, 2018

Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Investigational New Drugs 2019, 2019

Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. Bioorganic and Medicinal Chemistry Letters 28(19): 3202-3205, 2018

Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. Molecules 24(8), 2019